Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

Autor: Olivier Chosidow, Hervé Bachelez, Thomas Bettuzzi, Marie Beylot-Barry, Pascal Joly, Alain Dupuy, Florence Tubach, Emmanuel Mahé, Nathalie Beneton, Manuelle Viguier, Marie-Aleth Richard, Denis Jullien, Hugo Arlegui, Emilie Sbidian, Carle Paul

Publikováno v: Acta Dermato-Venereologica
Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩
Acta Dermato-Venereologica, Society for Publication of Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩

International audience; Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb6c5c9a9d7cf0f0d17ade051452590
https://hal.science/hal-03660920/file/Bettuzzi_document.pdf